| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
23,630,000 |
| Market
Cap: |
281.91(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.86 - $17.3 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 21.1 |
| Insider 6 Months : 21.7 |
| Insider 3/6 Months : 43.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PepGen is a clinical-stage biotechnology company. Co.'s primary product candidate is PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) peptide conjugated to a phosphorodiamidate morpholino oligomers (PMO) therapeutic cargo, which it is developing for the treatment of Duchenne muscular dystrophy (DMD) patients with mutations amenable to an exon 51-skipping approach. Co. is developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of myotonic dystrophy type 1. Co.'s second EDO therapeutic candidate for the treatment of DMD, and third product candidate, PGN-EDO53, is an EDO peptide-conjugated PMO designed to skip exon 53 of the dystrophin transcript.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,557,593 |
2,559,287 |
2,559,287 |
7,089,289 |
| Total Buy Value |
$27,212,790 |
$27,219,846 |
$27,219,846 |
$81,579,870 |
| Total People Bought |
1 |
2 |
2 |
5 |
| Total Buy Transactions |
1 |
2 |
2 |
6 |
| Total Shares Sold |
0 |
0 |
31,250 |
37,642 |
| Total Sell Value |
$0 |
$0 |
$505,357 |
$615,926 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
5 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Rajeev M. |
Director |
– • • |
2024-02-09 |
4 |
B |
$10.64 |
$27,212,790 |
I/I |
2,557,593 |
9,179,273 |
2.25 |
-20% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-11-30 |
4 |
B |
$4.17 |
$7,056 |
D/D |
1,694 |
1,694 |
2.81 |
159% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-08 |
4 |
AS |
$16.04 |
$38,188 |
D/D |
(2,381) |
0 |
|
-66% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-08 |
4 |
OE |
$2.71 |
$6,453 |
D/D |
2,381 |
2,381 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-07 |
4 |
AS |
$16.23 |
$136,618 |
D/D |
(8,419) |
0 |
|
-66% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-07 |
4 |
OE |
$2.71 |
$22,815 |
D/D |
8,419 |
8,419 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-06 |
4 |
AS |
$16.18 |
$293,660 |
D/D |
(18,150) |
0 |
|
-65% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-06 |
4 |
OE |
$2.71 |
$49,187 |
D/D |
18,150 |
18,150 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-05 |
4 |
AS |
$16.06 |
$8,028 |
D/D |
(500) |
0 |
|
-64% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-05 |
4 |
OE |
$2.71 |
$1,355 |
D/D |
500 |
500 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-02 |
4 |
AS |
$16.04 |
$28,863 |
D/D |
(1,800) |
0 |
|
-67% |
|
| Mcarthur James G |
President and CEO |
• • – |
2023-06-02 |
4 |
OE |
$2.71 |
$4,878 |
D/D |
1,800 |
1,800 |
|
- |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-03-24 |
4 |
AS |
$20.00 |
$7,840 |
D/D |
(392) |
0 |
|
-63% |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-03-24 |
4 |
OE |
$10.88 |
$4,265 |
D/D |
392 |
392 |
|
- |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-08 |
4 |
AS |
$17.00 |
$10,948 |
D/D |
(644) |
0 |
|
-41% |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-08 |
4 |
OE |
$10.88 |
$7,007 |
D/D |
644 |
644 |
|
- |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-07 |
4 |
AS |
$17.18 |
$63,213 |
D/D |
(3,679) |
0 |
|
-29% |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-07 |
4 |
OE |
$10.88 |
$40,028 |
D/D |
3,679 |
3,679 |
|
- |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-06 |
4 |
AS |
$17.04 |
$28,568 |
D/D |
(1,677) |
0 |
|
-24% |
|
| Goyal Jaya |
EVP, Res. & Preclin. Dev. |
• • – |
2023-02-06 |
4 |
OE |
$10.88 |
$18,246 |
D/D |
1,677 |
1,677 |
|
- |
|
| Svenstrup Niels |
SVP, Chem. Mfg & Controls |
• • – |
2022-12-19 |
4 |
OE |
$2.71 |
$27,100 |
D/D |
10,000 |
10,000 |
|
- |
|
| Oxford Sciences Innovation Plc |
|
– – • |
2022-05-10 |
4/A |
B |
$12.00 |
$10,559,640 |
D/D |
879,970 |
4,755,388 |
0.01 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2022-05-10 |
4 |
A |
$0.00 |
$0 |
I/I |
4,902,752 |
207,672 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2022-05-10 |
4 |
B |
$12.00 |
$38,750,400 |
I/I |
3,229,200 |
1,302,600 |
2.25 |
-53% |
|
| Deerfield Private Design Fund V, L.p. |
Possible Member of 10% Group |
– – • |
2022-05-10 |
4 |
B |
$12.00 |
$4,999,992 |
I/I |
416,666 |
476,813 |
1.5 |
-53% |
|
29 Records found
|
|
Page 1 of 2 |
|
|
0.23 (1.97%) 
